Make target identification failure a thing of the past

 

Your challenges and opportunities

You probably know that on average it takes between 10 to 121 years and $1.5 to $3B2 to bring a new drug to market, but did you know that:

<10% of drugs that enter clinical trials end up making it to market1
$800M is the low end estimated cost of a failed clinical trial3
40% of clinical trial failures are because no clear link is ever made between the target and the disease4

Fortunately new tools are now available to reduce the potential for target identification failure, greatly improving your chance of developing a first-in-class or best-in-class drug. Read the article below to learn more.

2015 logo

Article - The 21st Century Gold Rush: Novel Molecular Targets

Learn why target identification is the most important step in discovering your next potential blockbuster drug

Read the article

Want to Learn More?

If you’re interested in learning more about how you can reduce target identification failure, fill out our contact us form to have a member of our team reach out to you or visit our early research and preclinical website.

1. International, C. 2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY. (2015).
2. DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ 47, 20-33, doi:10.1016/j.jhealeco.2016.01.012 (2016).
3. https://www.clinicalleader.com/doc/the-high-price-of-failed-clinical-trials-time-to-rethink-the-model-0001
4. Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13, 419-431, doi:10.1038/nrd4309 (2014).
Current Customers
Quick Links
Global Sites
Follow